A5030497341- Ethics in Clinical Research
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Radiotherapy Techniques
- HER2/EGFR in Cancer Research
- Fullerene Chemistry and Applications
- Medical Imaging Techniques and Applications
- Advanced Breast Cancer Therapies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Barrier Structure and Function Studies
- Carbon Nanotubes in Composites
- Cell Adhesion Molecules Research
- Graphene and Nanomaterials Applications
- Groundwater and Isotope Geochemistry
- Breast Cancer Treatment Studies
- Economic and Financial Impacts of Cancer
- Glycosylation and Glycoproteins Research
- Fluoride Effects and Removal
Universidade Federal de São Paulo
2024
Translational Research in Oncology
2019
University of California, Los Angeles
2019
Translational Research in Oncology
2018-2019
University of Alberta
2018
CLDN6 is expressed at high levels in multiple cancers with little to no expression normal tissues and has been implicated the initiation, progression, metastasis of some cancers. an ideal target for development new therapeutics. TORL-1-23 first-in-class ADC targeting tumor-specific antigen CLDN6. This ongoing first human study (TORL123-001, NCT05103683) characterizes safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), recommended phase 2 (RP2D) participants...
Groundwater is the largest freshwater reserve on planet, and its quality plays a fundamental role in human well-being economic development. However, it sometimes contains potentially harmful compounds, such as fluoride high concentrations, which has led to implementation of standards ensure water potability. This study evaluates concentrations groundwater from state Paraguarí, Paraguay, studies joint occurrence with elements calcium, magnesium, sodium, potassium. Forty-one samples were...
Abstract Introduction: Central Nervous System (CNS) metastases as first site of relapse is seen in 2-3% patients with HER2+ early breast cancer (EBC) during or after treatment adjuvant trastuzumab. Data about long-term follow-up outcomes this population scarce. Methodology: BCIRG-006 was designed to assess the efficacy and safety two trastuzumab-based regimens compared a standard (non-trastuzumab) regimen EBC. 3,222 were randomized AC-T (AC-TH TCH). Ten year previously presented; we have...
Abstract Introduction: Adverse event (AE) reporting in clinical trials (CT) informs the safety of investigational products. Once approved, information monograph and prescribing mainly derive from CT data. Some studies have shown geographic variations AE patterns multinational CT; none them assessed this variation cancer CT. We conducted a study to analyze two breast (BC) by Translational Research Oncology (TRIO). Objective: To perform quantitative qualitative comparison non-serious (NSAE)...
Abstract Introduction: Latin America (LATAM) is among the so-called emerging regions for conducting clinical trials. Complex not-harmonized regulatory frameworks and lengthy approval timelines (among other factors) present challenges increased LATAM trial participation. Objective: to assess contribution trials, we conducted a descriptive analysis of region participation in practice-changing breast cancer (BC) Methodology: defined as any one that supported FDA new drug or indication...